MiR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

ABSTRACT: BACKGROUND:Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the first and rate-limiting step in converting tryptophan to kynurenine. Chimeric antigen receptor (CAR) T cells are T cells with recombinant receptors targeting tumor-associated antigens. The Food and Drug Administration has approved CAR T cells that target CD19 for treatment of advanced B cell leukemia and lymphoma. However, CAR T cell therapy in solid tumors has been hampered by multiple obstacles. Preclinical and clinical studies suggest that combinatorial immune checkpoint blockade and IDO1 inhibition provide durable therapeutic efficacy against cancer. Yet, the combination of IDO1 inhibition and CAR T has not been attempted. METHODS:We analyze IDO1 downregulation by miR-153 in colon cancer cells and the association of IDO1 and

SUBMITTER: Huang Q 

PROVIDER: S-EPMC5914051 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature